Evidence map›Paper›PMID 40676066›Full record

ArticleScientific reports2025

Light-activated multimodal nanoplatform for enhanced synergistic therapy of breast cancer.

Yu Liu, Senyi Gong, Waleed Aldahmash, Kamran Ashraf, Zhanxia Li, Imran Mahmood Khan, Sobia Niazi, Meijin Guo, Ali Mohsin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yu Liu *State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, 130 Meilong Rd., Shanghai, 200237, People's Republic of China.
Senyi Gong *State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, 130 Meilong Rd., Shanghai, 200237, People's Republic of China.
Waleed AldahmashZoology Department, College of Science, King Saud University, P. O. Box 2455, Riyadh, 11451, Saudi Arabia.
Kamran AshrafState Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, 130 Meilong Rd., Shanghai, 200237, People's Republic of China.
Zhanxia LiDepartment of Respiratory Medicine, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Imran Mahmood KhanNottingham Ningbo China Beacons of Excellence Research and Innovation Institute, University of Nottingham Ningbo China, Ningbo, 315100, China. imk2654@hotmail.com.
Sobia NiaziState Key Laboratory of Food Science and Technology, Jiangnan University, Wuxi, China.
Meijin GuoState Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, 130 Meilong Rd., Shanghai, 200237, People's Republic of China. guo_mj@ecust.edu.cn.ORCID http://orcid.org/0000-0002-3171-4802
Ali MohsinState Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, 130 Meilong Rd., Shanghai, 200237, People's Republic of China. alimohsin@ecust.edu.cn.

Funding

National Natural Science Foundation of China W2433060 & 22250410275Researchers Supporting Project , King Saud University, Riyadh, Saudi Arabia RSPD2025R1080
6 · The paper itself

Abstract

Breast cancer poses a significant health threat to women, as traditional chemotherapy often fails due to multidrug resistance and tumor adaptability. Moreover, the anti-apoptotic nature of these tumors limits the effectiveness of conventional treatments. Current therapeutic approaches, including photodynamic therapy (PDT), face limitations in clinical application due to poor water solubility of photosensitizers and challenges in targeted delivery. This study aims to develop a multifunctional nanosystem that integrates PDT with gene therapy to enhance breast cancer treatment efficacy. Firstly, Fe

Indexed as

Breast NeoplasmsPhotochemotherapyPhotosensitizing AgentsAnimalsApoptosisCell Line, TumorCombined Modality TherapyFemaleGenetic TherapyHumansHyaluronic AcidIndolesLightMCF-7 CellsMice2-(2-(2-chloro-3-((1,3-dihydro-3,3-dimethyl-1-propyl-2H-indol-2-ylidene)ethylidene)-1-cyclohexen-1-yl)ethenyl)-3,3-dimethyl-1-propylindoliumHyaluronic AcidIndolesPhotosensitizing AgentsBreast cancerFe3O4 Hollow nanosphereGene therapyPhotodynamic therapyTarget anti-apoptotic

Identifiers

PMID40676066
PMCPMC12271506

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.